Polivy (polatuzumab vedotin)
Polivy is an anti-CD79b antibody-drug conjugate (ADC). Polivy is currently approved in combination with bendamustine plus rituximab in the US for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, who have received at least two prior therapies, and in Europe for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for a haematopoietic stem cell transplant. Polivy in combination with bendamustine plus rituximab is also approved in five other countries.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.